New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:34 EDTBMRN, RGENRepligen announces asset purchase agreement with BioMarin for HDACi Portfolio
Repligen (RGEN) announced that it has entered into an asset purchase agreement with BioMarin Pharmaceutical (BMRN) to advance Repligen's histone deacetylase inhibitor, or HDACi, portfolio. The HDACi portfolio includes multiple orally bioavailable small molecule compounds as well as enabling technologies. Under the terms of the agreement, Repligen will receive an upfront payment of $2M from BioMarin and it has the potential to receive up to $160M in future milestone payments for the development, regulatory approval and commercial sale of portfolio compounds included in the agreement. In addition, Repligen is eligible to receive royalties on sales of therapeutic products originating from the HDACi portfolio. Potential applications of the HDACi portfolio include Friedreich's ataxia and other neurological disorders.
News For RGEN;BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
08:01 EDTBMRNPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 11, 2014
10:21 EDTBMRNHigh option volume stocks
Subscribe for More Information
07:46 EDTBMRNBioMarin could be $150 in 'blue skies' scenario, says UBS
Subscribe for More Information
07:35 EDTBMRNBioMarin price target raised to $107 from $92 at Leerink
Subscribe for More Information
07:24 EDTBMRNBioMarin price target raised to $104 from $90 at William Blair
William Blair raised its price target for BioMarin shares to $104 following the company's R&D day and keeps an Outperform rating on the stock. The firm expects the Vimizim launch to remain strong and believes BioMarin holds one of the strongest pipelines in the sector.
07:19 EDTBMRNBioMarin price target raised to $118-$122 from $103-$107 at Wells Fargo
Subscribe for More Information
December 10, 2014
08:14 EDTBMRNBioMarin VIMIZIM approved in Brazil
Subscribe for More Information
08:13 EDTBMRNBioMarin NAGLU granted ODD by FDA
Subscribe for More Information
December 9, 2014
12:22 EDTBMRNPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
07:44 EDTBMRNAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use